Cargando…
Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract
BACKGROUND: The well-known traditional Chinese herbal formula Guizhi Fuling Wan (GFW) was recently reported to improve the curative effects of chemotherapy for ovarian cancer with few clinical side effects. The present study aimed to investigate the reversal mechanism of sera derived from rats expos...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076886/ https://www.ncbi.nlm.nih.gov/pubmed/32066429 http://dx.doi.org/10.1186/s12906-020-2825-9 |
_version_ | 1783507308944293888 |
---|---|
author | Han, Li Cao, Xueyun Chen, Zhong Guo, Xiaojuan Yang, Lei Zhou, Yubing Bian, Hua |
author_facet | Han, Li Cao, Xueyun Chen, Zhong Guo, Xiaojuan Yang, Lei Zhou, Yubing Bian, Hua |
author_sort | Han, Li |
collection | PubMed |
description | BACKGROUND: The well-known traditional Chinese herbal formula Guizhi Fuling Wan (GFW) was recently reported to improve the curative effects of chemotherapy for ovarian cancer with few clinical side effects. The present study aimed to investigate the reversal mechanism of sera derived from rats exposed to Guizhi Fuling Wan extract (GFWE) in cisplatin-resistant human ovarian cancer SKOV3/DDP cells; the proteins examined included phosphatase and tensin homolog (PTEN) and metadherin (MTDH), and the possible protein interaction between PTEN and MTDH was explored. METHODS: GFWE was administered to healthy Wistar rats, and the sera were collected after five days. The PubMed and CNKI databases were searched for literature on the bioactive blood components in the sera. The systemsDock website was used to predict potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses were used to analyze the mRNA and protein levels of MTDH and PTEN. Laser confocal microscopy and coimmunoprecipitation (co-IP) were used to analyze the colocalization and interaction between MTDH and PTEN. RESULTS: Sixteen bioactive compounds were identified in GFWE sera after searching the PubMed and CNKI databases. The systemsDock website predicted the potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses showed decreased MTDH expression and increased PTEN expression in the sera. Laser confocal microscopy images and coimmunoprecipitation (co-IP) analyses demonstrated that a colocalization and interaction occurred between MTDH and PTEN, and the addition of the sera changed the interaction status. CONCLUSIONS: GFWE restored sensitivity to cisplatin by inhibiting MTDH expression, inducing PTEN expression, and improving the interaction between MTDH and PTEN in SKOV3/DDP cells, and these proteins and their interaction may serve as potential targets for cancer treatment. The sera may represent a new source of anticancer compounds that could help to manage chemoresistance more efficiently and safely. |
format | Online Article Text |
id | pubmed-7076886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70768862020-03-19 Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract Han, Li Cao, Xueyun Chen, Zhong Guo, Xiaojuan Yang, Lei Zhou, Yubing Bian, Hua BMC Complement Med Ther Research Article BACKGROUND: The well-known traditional Chinese herbal formula Guizhi Fuling Wan (GFW) was recently reported to improve the curative effects of chemotherapy for ovarian cancer with few clinical side effects. The present study aimed to investigate the reversal mechanism of sera derived from rats exposed to Guizhi Fuling Wan extract (GFWE) in cisplatin-resistant human ovarian cancer SKOV3/DDP cells; the proteins examined included phosphatase and tensin homolog (PTEN) and metadherin (MTDH), and the possible protein interaction between PTEN and MTDH was explored. METHODS: GFWE was administered to healthy Wistar rats, and the sera were collected after five days. The PubMed and CNKI databases were searched for literature on the bioactive blood components in the sera. The systemsDock website was used to predict potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses were used to analyze the mRNA and protein levels of MTDH and PTEN. Laser confocal microscopy and coimmunoprecipitation (co-IP) were used to analyze the colocalization and interaction between MTDH and PTEN. RESULTS: Sixteen bioactive compounds were identified in GFWE sera after searching the PubMed and CNKI databases. The systemsDock website predicted the potential PTEN/MTDH interactions with the compounds. RT-qPCR, western blotting, and immunofluorescence analyses showed decreased MTDH expression and increased PTEN expression in the sera. Laser confocal microscopy images and coimmunoprecipitation (co-IP) analyses demonstrated that a colocalization and interaction occurred between MTDH and PTEN, and the addition of the sera changed the interaction status. CONCLUSIONS: GFWE restored sensitivity to cisplatin by inhibiting MTDH expression, inducing PTEN expression, and improving the interaction between MTDH and PTEN in SKOV3/DDP cells, and these proteins and their interaction may serve as potential targets for cancer treatment. The sera may represent a new source of anticancer compounds that could help to manage chemoresistance more efficiently and safely. BioMed Central 2020-02-17 /pmc/articles/PMC7076886/ /pubmed/32066429 http://dx.doi.org/10.1186/s12906-020-2825-9 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Han, Li Cao, Xueyun Chen, Zhong Guo, Xiaojuan Yang, Lei Zhou, Yubing Bian, Hua Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract |
title | Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract |
title_full | Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract |
title_fullStr | Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract |
title_full_unstemmed | Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract |
title_short | Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract |
title_sort | overcoming cisplatin resistance by targeting the mtdh-pten interaction in ovarian cancer with sera derived from rats exposed to guizhi fuling wan extract |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076886/ https://www.ncbi.nlm.nih.gov/pubmed/32066429 http://dx.doi.org/10.1186/s12906-020-2825-9 |
work_keys_str_mv | AT hanli overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract AT caoxueyun overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract AT chenzhong overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract AT guoxiaojuan overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract AT yanglei overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract AT zhouyubing overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract AT bianhua overcomingcisplatinresistancebytargetingthemtdhpteninteractioninovariancancerwithseraderivedfromratsexposedtoguizhifulingwanextract |